Aurobindo Pharma Ltd has posted consolidated net profit of Rs 18.6 crore in the first quarter ended June 30.
In the corresponding quarter of the previous financial year, the company suffered a net loss of Rs 129 crore.
Revenue increased to Rs 1,699 crore (Rs 1,197 crore).
“Our focus on costs and the qualitative aspect of sales across key markets have reflected positively on our revenues and operating margins on a year-on-year basis,” Managing Director N. Govindarajan said in a release.
The net profit was impacted by the mark-to-market component of its dollar-denominated debt because of the rupee depreciation during the quarter, he added.
Formulations sales in the US increased 90 per cent at Rs 624 crore, followed by the EU and rest of the world at 52.6 per cent. Formulations constituted 63 per cent of gross sales while the remaining was from the active pharmaceutical ingredients segment.
naga.gunturi@thehindu.co.in